VAI TRÒ CỦA NỒNG ĐỘ MỘT SỐ DẤU ẤN CHU CHUYỂN XƯƠNG TRONG THEO DÕI ĐIỀU TRỊ LOÃNG XƯƠNG Ở PHỤ NỮ CAO TUỔI

Abstract

Objectives: To assess the role of serum Osteocalcin (OC) and Beta-CrossLaps (β-CTX) levels in monitoring treatment response with Alendronate in elderly women with osteoporosis. Subjects and methods: A longitudinal study enrolled 58 elderly women (≥ 60 years old) with osteoporosis treated with Alendronate at the Department of Rheumatology and Geriatrics Clinic, University Medical Center in Ho Chi Minh City from October 2021 to October 2022. The patients’ demographic information, routine blood tests, and serum levels of OC and β-CTX were recorded before and after 12 weeks of Alendronate treatment. Results: After 12 weeks of follow-up, of 58 participants, 21 elderly women with osteoporosis returned for their scheduled visit and had their serum levels of Osteocalcin and β-CTX tested before and after oral Alendronate treatment, at a dose of 70mg per week along with recommended vitamin D and calcium supplements. In elderly women with osteoporosis receiving Alendronate, the Osteocalcin level was found to decrease by 52.22% (33.08 – 52.99%) with a change of 10.4 (7.8-15.3) ng/ml before and after treatment with p<0.001. Similarly, the serum β-CTX level experienced an 80% reduction (70.00 – 81.37%) with a difference of 0.477 (0.374 – 0.500) ng/ml between pre-treatment and post-treatment measurements, with p<0.001. Based on the least significant change (LSC) threshold for serum Osteocalcin level, 80.95% of the participants demonstrated a treatment response, while 90.48% exhibited a treatment response according to both the LSC threshold and the reference interval (RI) of premenopausal women for serum β-CTX level. Conclusion: In elderly women with osteoporosis, a significant decrease in serum levels of OC and β-CTX was observed following a 12-week course of Alendronate treatment. The reduction in serum levels of OC and β-CTX indicate the short-term effectiveness of the therapy and aid in enhancing patient adherence. Furthermore, monitoring the changes in serum levels of OC and β-CTX enables clinicians to assess treatment response and take timely interventions when required.